Biodexa Pharmaceuticals (BDRX) Non-Current Assets (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Non-Current Assets of $7.6 million for Q4 2025, down 1.93% sequentially from $7.8 million in Q2 2025, and little changed YoY from $7.7 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Non-Current Assets (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Non-Current Assets for 13 years, with the latest figure at $7.6 million in Q4 2025.
- Quarterly Non-Current Assets changed 0.43% year-over-year to $7.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.2 million (up 59.75% YoY) and the FY2025 annual result came in at $7.6 million, down 1.3% from the prior year.
- Non-Current Assets retreated to $7.6 million in Q4 2025 per BDRX's latest filing, from $7.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $8.1 million in Q2 2024 and troughed at $873451.5 in Q2 2023.
- A 5-year average of $4.2 million and a median of $3.1 million in 2021 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets tumbled 36.78% in 2022, then jumped 831.22% in 2024.
- Over 5 years, Non-Current Assets stood at $1.6 million in 2021, then sank by 36.78% to $981741.0 in 2022, then soared by 344.0% to $4.4 million in 2023, then surged by 75.79% to $7.7 million in 2024, then decreased by 0.43% to $7.6 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $7.6 million, $7.8 million, and $7.7 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 18.06 Bn |
| 10 | Biodexa Pharmaceuticals | 65,093.53 | -11.29 Mn | - | 7.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.63 Mn |
| Jun 30, 2025 | 7.78 Mn |
| Dec 31, 2024 | 7.66 Mn |
| Jun 30, 2024 | 8.13 Mn |
| Dec 31, 2023 | 4.36 Mn |
| Jun 30, 2023 | 873,451.48 |
| Dec 31, 2022 | 981,741.00 |
| Jun 30, 2022 | 1.25 Mn |
| Dec 31, 2021 | 1.55 Mn |
| Jun 30, 2021 | 1.74 Mn |
| Dec 31, 2020 | 715,684.44 |
| Jun 30, 2020 | 2.15 Mn |
| Dec 31, 2019 | 22.06 Mn |
| Jun 30, 2019 | 18.27 Mn |
| Dec 31, 2018 | 19.08 Mn |
| Jun 30, 2018 | 20.93 Mn |
| Dec 31, 2017 | 40.68 Mn |
| Jun 30, 2017 | 42.90 Mn |
| Dec 31, 2016 | 42.75 Mn |
| Jun 30, 2016 | 65.15 Mn |